Treatment of early-stage nonbulky Hodgkin lymphoma

Current Opinion in Oncology

Volumn 18, Issue 5, 2006, Pages 432-436

  Straus, David J ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Early stage nonbulky Hodgkin lymphoma

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; NAVELBINE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; DYSPNEA; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; INFECTION; LEUKOPENIA; LUNG TOXICITY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PHARYNX DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA, NON-HODGKIN;

EID: 33746890160     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000239880.39086.94     Document Type: Review

References (32)

1. Blayney DW, Longo DL, Young RC, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987; 316:710-714.
2. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290:2831-2837.
3. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270: 1949-1955.
4. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22:3139-3148.
5. van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18:487-497.
6. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000; 18:498-509.
7. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002; 20:3484-3494.
8. Green DM, Hyland A, Barcos MP, et al. Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol 2000; 18:1492-1499.
9. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003; 21:4386-4394.
10. Zamecnik M, Mukensnabl P, Kracik M. Nemaline myopathy in neck muscle after radiotherapy. Hum Pathol 2004; 35:642-643.
11. Schierle C, Winograd JM. Radiation-induced brachial plexopathy: complication without a cure [review]. J Reconstr Microsurg 2004; 20:149-152.
12. Abratt RP, Morgan GW, Silvestri G, Willcox P. Pulmonary complications of radiation therapy. Clin Chest Med 2004; 25:167-177.
13. Loyer E, Fuller L, Libshitz HI, Palmer JL. Radiographic appearance of the chest following therapy for Hodgkin disease. Eur J Radiol 2000; 35:136-148.
14. Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22:2835-2841.
15. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21:3601-3608.
16. Engert A, Pluetschow A, Eich HT, et al. Combined modality treatment of two or four cycles of ABVD followed by involved field radiotherapy in the treatment of patients with early stage Hodgkin's lymphoma [abstract]. Blood 2005; 106:750a.
17. Koontz BF, Kirkpatrick JP, Clough RW, et al. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. J Clin Oncol 2006; 24:605-611.
18. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348:2396-2406.
19. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104:3483-3489.
20. Rueda Dominguez A, Marquez A, Guma J, et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004; 15:1798-1804.
21. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23:4634-4642. Randomized trial of two treatment algorithms in subsets of patients with earlystage Hodgkin lymphoma: 'standard' (extended-field radiotherapy or two cycles of ABVD + extended-field radiotherapy) vs. 'experimental' (four to six cycles of ABVD).
22. Eghbali H, Brice P, Creemers G-Y, et al. Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-F trial [abstract]. Blood 2005; 106:240a.
23. Noordijk EM, Carde P, Mandard AM, et al. Preliminary results of the EORTCGPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie. Ann Oncol 1994; 5 (Suppl 2):S107-S112.
24. Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005; 23:7614-7620. Retrospective analysis demonstrating a decreased survival in patients with Hodgkin lymphoma who have bleomycin-related pulmonary toxicity.
25. Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000; 18:2615-2619.
26. Zinzani PL, Bendandi M, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000; 85:926-929.
27. Bartlett ND, Johnson J, Friedberg JW, et al., for Cancer and Leukemia Group B. A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: preliminary results of CALGB 59804 [abstract]. Proc Am Soc Clin Oncol 2003; 22:566.
28. Bredenfeld H, Franklin J, Nogova L, et al. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2004; 22:2424-2429.
29. Friedberg JW, Neuberg D, Kim H, et al. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer 2003; 98:978-982.
30. Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43:1018-1027.
31. Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDGPET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16:1160-1168. Retrospective analysis of interim PET scanning after two or three chemotherapy cycles for Hodgkin lymphoma.
32. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107:52-59. Prospectively ascertained PET scanning after two cycles of chemotherapy for Hodgkin lymphoma, demonstrating predictive value for treatment failure and progression-free survival.